Open AccessThis article is
- freely available
Chemokines as Cancer Vaccine Adjuvants
Departments of General Surgery, School of Medicine, University Hospital Case Medical Center/Case Western Reserve University, Cleveland, OH 44106, USA
Departments of Pediatrics, School of Medicine, University Hospital Case Medical Center/Case Western Reserve University, Cleveland, OH 44106, USA
* Authors to whom correspondence should be addressed.
Received: 22 July 2013; in revised form: 31 August 2013 / Accepted: 26 September 2013 / Published: 16 October 2013
Abstract: We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach. Recent discoveries in the many biological roles of chemokines in tumor immunology allow their exploitation in enhancing recruitment of antigen presenting cells (APCs) and effector cells to appropriate anatomical sites. This knowledge, combined with advances in gene therapy and virology, allows researchers to employ chemokines as potential vaccine adjuvants. This review will focus on recent murine and human studies that use chemokines as therapeutic anti-cancer vaccine adjuvants.
Keywords: chemokines; dendritic cell; immunotherapy; cancer vaccine; adjuvant
Citations to this Article
Cite This Article
MDPI and ACS Style
Bobanga, I.D.; Petrosiute, A.; Huang, A.Y. Chemokines as Cancer Vaccine Adjuvants. Vaccines 2013, 1, 444-462.
Bobanga ID, Petrosiute A, Huang AY. Chemokines as Cancer Vaccine Adjuvants. Vaccines. 2013; 1(4):444-462.
Bobanga, Iuliana D.; Petrosiute, Agne; Huang, Alex Y. 2013. "Chemokines as Cancer Vaccine Adjuvants." Vaccines 1, no. 4: 444-462.